Total Funding
30
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
178179
Surface Oncology develops next-generation cancer immunotherapy treatments based on proprietary discoveries.
Acquired by 
Coherus Biosciences
- Wendy Dwyer: Chief Business Officer
Ben Montgomery: Senior Director, Corporate CounselPast Role: Partners Innovation Fund, Associate
About the Company
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play
vital roles in tumor immune evasion.
